Skip to search formSkip to main contentSkip to account menu

Fusion Toxin

A receptor-targeted complex comprised of a truncated toxin fused to a hormone, growth factor, or immunologic agent (i.e. antibody) that binds to the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) and accounts for 30%to 40%of… 
2007
2007
A Cell-permeable Fusion Toxin as a Tool to Study the Consequences of Actin-ADP-ribosylation Caused by the Salmonella enterica Virulence Factor SpvB in Intact Cells*
The virulence factor SpvB is a crucial component for the intracellular growth and infection process of Salmonella enterica. The… 
Highly Cited
2001
Highly Cited
2001
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
1999
1999
High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
A genetically engineered fusion toxin targeted to acute myeloid leukemic (AML) blasts was designed with the first 388 amino acid… 
1996
1996
Genetic construction and properties of a diphtheria toxin-related substance P fusion protein: in vitro destruction of cells bearing substance P receptors.
We have genetically replaced the native receptor binding domain of diphtheria toxin with an extended form of substance P (SP): SP… 
Highly Cited
1994
Highly Cited
1994
Phase I trial of an interleukin‐2 fusion toxin (DAB486IL‐2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy
Background. DAB486IL‐2 is a recombinant fusion toxin in which the native diphtheria toxin‐receptor binding‐domain has been… 
Review
1993
Review
1993
Recombinant fusion toxins--a new class of targeted biologic therapeutics.
The design and construction of a new class of recombinant therapeutic agents, receptor-specific cytotoxins, has occurred within… 
1992
1992
Interleukin 2 receptor targeted fusion toxin (DAB486‐IL‐2) treatment blocks diabetogenic autoimmunity in non‐obese diabetic mice
Insulin‐dependent diabetes mellitus (IDDM) is strikingly similar in the non‐obese diabetic (NOD) mouse and humans. In IDDM, the… 
1991
1991
Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.
We have used site-directed insertion and point mutagenesis in an attempt to increase the cytotoxic potency and receptor-binding… 
1991
1991
Interleukin 4 receptor targeted cytotoxicity: Genetic construction and in vivo immunosuppressive activity of a diphtheria toxin‐related murine interleukin 4 fusion protein
The interleukin 4 (IL 4) receptor is expressed on various cells of the immune system, including T and B lymphocytes, macrophages… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)